TF0066

TF0066 is a preclinical-stage small molecule prodrug being developed by Techfields for the treatment of neuropathic pain and depression. It is engineered using Techfields' proprietary prodrug modification platform, which is designed to enhance the transdermal penetration of clinically approved molecules into target tissues. By converting established drugs into prodrugs optimized for topical or transdermal delivery, Techfields aims to facilitate the crossing of tissue barriers more safely and effectively than via oral or intravenous routes. While the specific active pharmaceutical ingredient and its molecular targets have not been publicly disclosed, TF0066 represents an application of this technology to address neurological and psychiatric conditions.